#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Polycythaemia vera Ovarian cancer stage III Epstein-Barr virus infection Ewing's sarcoma recurrent Pyruvate dehydrogenase complex deficiency Cutaneous calcification Fibrous dysplasia of bone Extra-osseous Ewing's sarcoma recurrent Ovarian epithelial cancer Henoch-Schonlein purpura Growth hormone deficiency Sjogren's syndrome HER2 mutant non-small cell lung cancer Inborn error of metabolism Primitive neuroectodermal tumour More trials…

    Learn about Rare Diseases

    Hereditary hypophosphataemic rickets – Diagnostics Synovial sarcoma metastatic – Trials in Disease Cerebral arteriovenous malformation haemorrhagic – Diagnostics Mucous membrane pemphigoid – Treatment Adrenocortical carcinoma – Treatment Mucopolysaccharidosis II – Diagnostics Splenic marginal zone lymphoma – Trials in Disease Burkitt’s lymphoma – Treatment Chondrosarcoma metastatic – Life with Disease Pulmonary sarcoidosis – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Isoniazid Colistin Sulfate VMX-C001 Bintrafusp Alfa Olmesartan Medoxomil Roxadustat Oritavancin Lithium Fludarabine Phosphate Ph. Eur. Anhydrous Cholestyramine Dobutamine Teclistamab Etamsylate VX-993 Rintatolimod Istradefylline Cibotercept Enoxaparin Sodium Dexchlorpheniramine Maleate Regorafenib More therapies…

    Learn about Your Condition

    Athetosis Lung adenocarcinoma stage III Metabolic surgery Gestational diabetes Bipolar disorder Inborn error of metabolism Post procedural infection Urticaria cholinergic Malignant lymphoid neoplasm Ischaemic stroke Endolymphatic hydrops Glioblastoma Glycogen storage disorder Thrombosis Richter's syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University Of Debrecen

University Of Debrecen

Mhiwyn Zgnzuiyz Kkyoy 2xi Dbszgxkfx 4wvsv Hxsnrsz

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren’s Disease

    Not recruiting

    3 1
    Investigated Drugs:
    • Nipocalimab
    Austria Bulgaria Czechia Denmark France Germany +9

  • Study on Maridebart Cafraglutide for Adults with Type 2 Diabetes and Obesity or Overweight

    Not recruiting

    3 1
    Investigated Diseases:
    • Obesity
    • Overweight
    Investigated Drugs:
    • Maridebart Cafraglutide
    Bulgaria Czechia Germany Hungary Italy Poland

  • Study Comparing EYP-1901 and Aflibercept for Patients with Wet Age-Related Macular Degeneration

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Neovascular age-related macular degeneration
    Investigated Drugs:
    • VOROLANIB
    • Aflibercept
    Czechia Germany Hungary Poland Slovakia

  • Study on the Effectiveness and Safety of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • SALICYLIC ACID
    • Clindamycin Hydrochloride
    • Triamcinolone Acetonide
    Austria Belgium Czechia France Germany Greece +4

  • Study on the Effectiveness and Safety of Tildrakizumab for Patients with Moderate to Severe Genital Psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Tildrakizumab
    Bulgaria Hungary Poland

  • Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Jnj-77242113
    • Ustekinumab
    Austria Belgium Denmark Germany Hungary Poland +2

  • Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Envudeucitinib
    Austria Belgium Bulgaria Czechia Estonia France +7

  • Study on the Effect of Survodutide on Heart Safety in Patients with Obesity and Cardiovascular or Kidney Disease

    Not recruiting

    3 1
    Investigated Drugs:
    • BI 456906
    • SURVODUTIDE
    Austria Belgium Bulgaria Czechia Denmark Finland +11

  • Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Not Used Biologic Treatments

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Jnj-77242113
    • Ustekinumab
    Bulgaria Czechia Denmark Germany Hungary Poland +1

  • Study on Itepekimab for Adults with Chronic Rhinosinusitis and Nasal Polyps

    Not recruiting

    3 1
    Investigated Diseases:
    • Chronic rhinosinusitis with nasal polyps
    Investigated Drugs:
    • Itepekimab
    Austria Finland Germany Hungary Italy The Netherlands +4
Previous Page
1 … 25 26 27 28 29 … 52
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!